Business Wire

PA-KNOPP-BIOSCIENCES

Share
Knopp Biosciences NIH-Funded Pain Program Advances to Second Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain

Knopp Biosciences LLC today announced that it entered the second year of research funded by the National Institutes of Health (NIH) to utilize its Kv7 platform to discover and develop non-opioid therapies for the treatment of chronic pain. The project is funded by the NIH program called Helping to End Addiction Long-term (the NIH HEAL Initiative ), which aims to improve treatments for chronic pain, curb the rates of opioid use disorder and overdose, and achieve long-term recovery from opioid addiction.

Knopp has developed a discovery platform of proprietary molecules directed to a non-opioid biological target linked to chronic pain caused by damage to nerves. The drug target is a cellular membrane potassium channel called Kv7.2/7.3, which regulates the flow of electrically charged ions required to modulate the excitability of cells. Growing scientific evidence suggests that selectively activating key Kv7 channel subtypes can control nerve-cell hyperexcitability associated with chronic pain.

“Knopp is pleased that the achievement of year one milestones positioned the company to continue research on solutions for this public health crisis,” said Michael Bozik, M.D., Chief Executive Officer of Knopp. “In year two, we expect to identify a molecule from our Kv7 platform that is suitable for further development as a potential non-opioid treatment for patients suffering from certain types of chronic pain.”

The grant funding of as much as $8 million is contingent upon the attainment of milestones over five years. Knopp’s HEAL award was one of 375 grants made across 41 states in fiscal year 2019 to apply scientific solutions to help reverse the national opioid crisis.

Knopp's Kv7 research is supported in part under Award Number U44NS093160 and Award Number U44NS115732 of the National Institute of Neurological Disorders and Stroke of the NIH. The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases of high unmet need. Knopp’s clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for developmental and epileptic encephalopathies, other rare epilepsies, neuropathic pain, and tinnitus. Please visit www.knoppbio.com.

ABOUT THE NIH HEAL INITIATIVE

The Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM , is an aggressive, trans-NIH effort to speed scientific solutions to stem the national opioid public health crisis. Launched in April 2018, the initiative is focused on improving prevention and treatment strategies for opioid misuse and addiction, and enhancing pain management. For more information, visit: https://heal.nih.gov .

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing pre-clinical or clinical study to verify their safety and effectiveness.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting styrker sin platform med tilføjelsen af Baufest16.7.2025 20:07:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Baufest, et globalt firma inden for digitalt produktdesign og -udvikling. Med mere end 30 års erfaring og kontorer i hele Amerika og Europa er Baufest anerkendt for at kombinere banebrydende teknologi med en dybdegående forståelse af forretningsstrategi og brugeroplevelse. Firmaet tilbyder et omfattende udvalg af tjenester, der omfatter forretningsdesign, udvikling af digitale produkter, data og anvendt AI og cybersikkerhed. Baufest betjener virksomhedskunder på tværs af nøgleindustrier som bank og finans, detailhandel, energi og sundhedspleje med fokus på at skabe målbare forretningsresultater gennem smidig, skalerbar og etisk teknologipraksis. "Vores samarbejde med Andersen Consulting er et vigtigt skridt fremad for de tjenester, vi tilbyder," siger Ángel Pérez Puletti, administrerende direktør for Baufest. "Andersens fulde pakke af specialiserede tjenester bygger på Baufests

ProAmpac Releases 2025 Sustainability Impact Report: A Decade of Flexibility. A Future of Possibilities16.7.2025 18:54:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, announces the release of its 2025 Sustainability Impact Report. This year’s theme, A Decade of Flexibility. A Future of Possibilities. celebrates the company’s decade-long journey of sustainable innovation and sets the foundation for its forward-looking climate and packaging goals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716418035/en/ ProAmpac's 2025 Sustainability Impact Report “As we celebrate ten years of growth and innovation, we remain focused on what lies ahead: accelerating circular packaging, lowering our carbon footprint, and creating shared value for our employees, customers, communities, and partners. Our journey is far from over, but with every step, our purpose becomes clearer, and our momentum stronger,” said Greg Tucker, founder, vice-chairman, and chief executive officer of ProAmpac. Key highlights from the 2025 Impact Report incl

EBRD Extends Partnership With HTEC Through New Round of Financing16.7.2025 16:25:00 CEST | Press release

Loan to support company expansion€60 million EBRD financing to support HTEC’s expansionHTEC will use the funds for new acquisitionsThe EBRD continues to foster growth of the technology sector The European Bank for Reconstruction and Development (EBRD) is stepping up support for the Serbian technology industry by backing HTEC, a Serbia-founded AI-first engineering services and digital product development company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716157421/en/ EBRD extends partnership with HTEC through new round of financing. The Bank is providing a €60 million loan to support HTEC’s expansion through strategic acquisitions that will further improve the company’s positioning in key markets. The Bank is providing a €60 million loan to support HTEC’s expansion through strategic acquisitions that will further improve the company’s positioning in key markets. HTEC and the EBRD began their partnership in 2020 with

OpenX Announces OpenXSelect, an Advanced Supply-Side Targeting and Curation Platform for Brands and Agencies16.7.2025 16:05:00 CEST | Press release

OpenXSelect cuts deal setup time by 50% and doubles reach across CTV, native, app, and web. OpenX Technologies, Inc., a leading supply-side platform, today announced the general availability of OpenXSelect™, a next-generation curation and supply-side targeting platform for brands and agencies. Built to bring buyers closer to supply, OpenXSelect enables them to take full control of inventory quality, activate targeting at scale using a wide range of data—including audience, behavioral, attention, and sustainability—and optimize performance through a streamlined, intuitive interface. OpenX has been the leader in supply-side curation since 2018, when it launched OpenAudience™, a first-of-its-kind solution for data partners, powered by the industry’s first supply-side identity graph. OpenAudience set a new standard for activating audiences directly on the supply side and redefined what data-driven curation could look like. OpenXSelect™ builds on that legacy. Developed in close collaboratio

Interactive Brokers Unveils Investment Themes Tool to Turn Market Trends into Smarter Trades16.7.2025 16:00:00 CEST | Press release

New discovery feature helps investors quickly explore market trends, compare companies, and find opportunities Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced the release of Investment Themes, an intuitive discovery tool powered by Reflexivity that investors can use to move from market trends to actionable trade ideas more quickly and confidently. Available across IBKR’s powerful trading platforms, Investment Themes simplifies the research process by connecting companies, products, competitors, and regions across the entire S&P 1500 universe. The underlying thematic intelligence was developed by Reflexivity, leveraging its proprietary knowledge graph to map the real-world relationships between companies and their business drivers. Investment Themes turns complex market data into clear, interactive insights. Investors can start with a topic like “Generative AI” or “Nuclear Energy” and instantly view the public companies tied to that theme, without ne

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye